{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:30:30Z","timestamp":1790670630336,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"ANR Emergence grant","doi-asserted-by":"publisher","award":["ANR-12-EMMA-0011-01"],"award-info":[{"award-number":["ANR-12-EMMA-0011-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur Accelerating Preclinical Candidates - GPF\u2013 Vaccinology 2015","doi-asserted-by":"publisher","award":["GPFVacc2-08"],"award-info":[{"award-number":["GPFVacc2-08"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2020.01.014","type":"journal-article","created":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T16:06:34Z","timestamp":1579363594000},"page":"1888-1892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Subcutaneous vaccination with a live attenuated Yersinia pseudotuberculosis plague vaccine"],"prefix":"10.1016","volume":"38","author":[{"given":"Anne","family":"Derbise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Guillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Gerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Carniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pizarro-Cerd\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian E.","family":"Demeure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.01.014_b0005","unstructured":"Bertherat E. Plague around the world in 2019. In: WHO, editor. Weekly Epidemiologic Reports: WHO; 2019. p. 289\u201392."},{"key":"10.1016\/j.vaccine.2020.01.014_b0010","unstructured":"Feodorova VA, Motin VL. Plague vaccines. In: Motin VAFaVL, editor. Vaccines against bacterial biothreat pathogens. Kerala, India: Research SignPost; 2011. p. 175\u2013233."},{"key":"10.1016\/j.vaccine.2020.01.014_b0015","unstructured":"DynPort Vaccine Company. Recombinant Plague Vaccine rF1V in Healthy Volunteers. Clinical Trials.gov: NIH. U.S. National Library of Medicine; 2011."},{"key":"10.1016\/j.vaccine.2020.01.014_b0020","unstructured":"Jiangsu Province CDC. Immunogenicity and Safety of Subunit Plague Vaccine. Clinical Trials.gov: NIH. U.S. National Library of Medicine; 2015."},{"key":"10.1016\/j.vaccine.2020.01.014_b0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.21055\/0370-1069-2019-1-50-63","article-title":"Current state of the problem of vaccine development for specific prophylaxis of plague","volume":"1","author":"Mikshis","year":"2019","journal-title":"Problems Particul Dangerous Infect (Russian)"},{"key":"10.1016\/j.vaccine.2020.01.014_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004162","article-title":"Complete protection against pneumonic and bubonic plague after a single oral vaccination","volume":"9","author":"Derbise","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.01.014_b0035","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.coi.2012.03.014","article-title":"Vaccines against mucosal infections","volume":"24","author":"Holmgren","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2020.01.014_b0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1741-7007-8-129","article-title":"Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine","volume":"8","author":"Levine","year":"2010","journal-title":"BMC Biol"},{"key":"10.1016\/j.vaccine.2020.01.014_b0045","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1016\/j.vaccine.2006.11.058","article-title":"Biological safety concepts of genetically modified live bacterial vaccines","volume":"25","author":"Frey","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.014_b0050","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.vaccine.2009.02.071","article-title":"Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication","volume":"27","author":"Minor","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.014_b0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nri1310","article-title":"Immune surveillance in the skin: mechanisms and clinical consequences","volume":"4","author":"Kupper","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2020.01.014_b0060","article-title":"An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague","volume":"6","author":"Derbise","year":"2012","journal-title":"PLoS NTD"},{"key":"10.1016\/j.vaccine.2020.01.014_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217440","article-title":"Shift from primary pneumonic to secondary septicemic plague by decreasing the volume of intranasal challenge with Yersinia pestis in the murine model","volume":"14","author":"Olson","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.014_b0070","doi-asserted-by":"crossref","first-page":"L833","DOI":"10.1152\/ajplung.00173.2001","article-title":"Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia","volume":"282","author":"Southam","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.vaccine.2020.01.014_b0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.vaccine.2018.11.022","article-title":"Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine","volume":"37","author":"Demeure","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.014_b0080","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/IAI.01495-07","volume":"76","author":"Zhao","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.01.014_b0085","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1146\/annurev-immunol-051116-052215","article-title":"Antigen-Presenting Cells in the Skin","volume":"35","author":"Kashem","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2020.01.014_b0090","unstructured":"Iannelli V. Which Vaccines can be Given SQ? In: Vaxopedia, editor; 2019. p. vaxopedia.org\/2018\/04\/10\/which-vaccines-can-be-given-sq\/."},{"key":"10.1016\/j.vaccine.2020.01.014_b0095","first-page":"211","article-title":"The history of live bacterial vaccines","volume":"84","author":"Lindberg","year":"1995","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2020.01.014_b0100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1086\/649557","article-title":"Resilience to bacterial infection: difference between species could be due to proteins in serum","volume":"201","author":"Warren","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.014_b0105","doi-asserted-by":"crossref","first-page":"24922","DOI":"10.1074\/jbc.M114.566570","article-title":"Modulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutants","volume":"289","author":"Rossi","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.01.014_b0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-018-0084-5","article-title":"The immunological anatomy of the skin","volume":"19","author":"Kabashima","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2020.01.014_b0115","doi-asserted-by":"crossref","unstructured":"Quereda JJ, Nahori MA, Meza-Torres J, Sachse M, Titos-Jimenez P, Gomez-Laguna J, et al. Listeriolysin S Is a Streptolysin S-Like Virulence Factor That Targets Exclusively Prokaryotic Cells In Vivo. MBio. 2017;8.","DOI":"10.1128\/mBio.00259-17"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20300189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20300189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:39:53Z","timestamp":1759401593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20300189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X20300189"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.014","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/822221","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous vaccination with a live attenuated Yersinia pseudotuberculosis plague vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}